In-House Veterinary Diagnostics: The Market Expansion Your Clinic Customers Are Looking For

The single largest shift in veterinary diagnostics over the past five years has not been a new technology — it has been where testing happens. In-clinic diagnostic platforms are displacing send-out laboratory services at a rate that is creating sustained, multi-year demand for haematology analysers, biochemistry platforms, urinalysis systems and point-of-care electrolyte devices. For veterinary equipment distributors, this shift represents one of the most durable revenue opportunities in the current market.

Why clinics are moving in-house

The economics of send-out diagnostics are becoming increasingly difficult to justify for high-volume practices:

• Turnaround time — send-out results typically take 12–48 hours. In-house results are available in 3–15 minutes. For pre-anaesthetic screening, emergency triage and hospitalised patients, in-house speed changes the clinical decision timeline entirely.
• Cost per test — at high monthly volumes, in-house cost per test frequently undercuts send-out pricing. The break-even point for most analyser platforms is reached at 80–120 tests per month — a volume most established small-animal practices exceed.
• Client expectation — urban pet owners increasingly expect same-appointment results. Clinics that deliver them retain clients more effectively than those referring all diagnostics out.
• Competitive differentiation — in clinic networks and hospital chains, in-house diagnostics are a tier-1 capability that supports premium pricing and specialist case referrals.

What the distributor sells

The in-clinic diagnostics category has two revenue layers:

1. Capital equipment — the analyser platforms themselves. These are typically replaced on 5–7 year cycles, generating capital purchase revenue.
2. Consumables — reagent cartridges, reagent kits, control solutions, calibrators, cuvettes. These are purchased monthly and generate revenue in direct proportion to clinic diagnostic volume. At 200 tests per month, annual consumable revenue per installed unit typically equals 80–140% of the original equipment purchase price.

Platform selection for the distributor’s portfolio

A practical in-clinic diagnostics portfolio for a veterinary distributor requires four platform types:

• Haematology analyser — CBC, reticulocyte count, differential. Entry-level units with veterinary species validation are the highest-volume seller in this category.
• Biochemistry analyser — pre-anaesthetic panels, liver/renal/electrolyte profiles. Cassette or wet-chemistry platforms; choice depends on clinic throughput and cold-chain reliability in the target market.
• Urinalysis system — automated sediment and dipstick. Often the third platform purchased by a clinic, after haematology and biochemistry are established.
• Point-of-care electrolyte — compact, fast, low consumable cost. Particularly valued in emergency and critical-care environments.

Market entry approach

Distributor market entry in in-clinic diagnostics typically follows the capital equipment sale. A clinic that has already purchased DR imaging through your distribution channel is a warm lead for haematology and biochemistry platforms — the capital equipment relationship is already established. Diagnostic bundling (imaging + lab at combined pricing) accelerates both sales cycles and increases average order value per clinic account.

IWA Medical supplies haematology, biochemistry and urinalysis platforms validated for veterinary species with full distributor margin support and consumable supply chain. Request our in-clinic diagnostics distributor pack to start the conversation.

Interested in distributing IWA Medical products? Browse our full catalogue at iwamed.com or contact our partnerships team at partners@iwamed.com.